BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $180 to $214.
BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $214
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.